1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

US FDA's Next-Gen Sequencing Guidances: One Stop On A Pathway

Two recent next-generation sequencing draft guidances have been positively received so far by industry and clinical research groups. But for FDA's ideas to play out, more databases will need to be populated and more standards developed, agency officials say. There are also more guidances to come on different types of NGS tests. Read our coverage below, and also listen to our podcast interview with FDA's Elizabeth Mansfield.

DNA

US FDA hopes its two recent draft-guidance documents for companies developing next-generation sequencing diagnostics will spur development of new NGS databases and standards – the very tools that the guidance documents rely on to outline a new regulatory paradigm for these assay types.

The agency issued a draft guideline earlier this month addressing how to employ standards to support regulatory approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

MHRA’s Tallon Lays Out His Philosophy On Healthcare Products Regulation

 
• By Ashley Yeo

June Raine was a “hard act to follow” at MHRA, but new chief executive Lawrence Tallon is looking to the future in setting out a vision for the UK regulator.

HistoSonics Closed $250M Funding To Expand, But IPO ‘Not Immediate Priority,’ Says CEO

 
• By Marion Webb

The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.

Successful Diagnostics Alter Clinical Pathways, Says NHS Foundation Trust Leader

 
• By Natasha Barrow

Evidence-based testing in real clinical settings and diagnostics tailored to community needs are crucial adoption success factors for new IVDs, Michael Wright, joint medical director at Newcastle Hospitals NHS Foundation Trust, told Medtech Insight at a regional UK meeting.

MedTech Innovator Winner Armor Medical Hopes To Reduce 90% Of Preventable Maternal Deaths

 
• By Marion Webb

Armor Medical’s wrist-worn wearable detected postpartum hemorrhage five times earlier than standard care in earlier studies. After surviving near-fatal hemorrhage herself, co-founder/CEO Kelsey Mayo aims to bring the device to market in 2028.

More from Device Area

Medicare’s TCET Pathway Wins Acclaim From Early Users, Even As ‘Messy Middle’ Persists

 
• By Brian Bossetta

Some of the first manufacturers to receive Medicare coverage for their breakthrough devices through the Transitional Coverage for Emerging Technologies pathway praise CMS’ engagement and timelines in the process, despite some challenges around post-launch data collection.

HistoSonics Closed $250M Funding To Expand, But IPO ‘Not Immediate Priority,’ Says CEO

 
• By Marion Webb

The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.

Successful Diagnostics Alter Clinical Pathways, Says NHS Foundation Trust Leader

 
• By Natasha Barrow

Evidence-based testing in real clinical settings and diagnostics tailored to community needs are crucial adoption success factors for new IVDs, Michael Wright, joint medical director at Newcastle Hospitals NHS Foundation Trust, told Medtech Insight at a regional UK meeting.